This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
After the drug discovery specialist Evotec SE lowered its annual forecast and lost almost 75% of its market capitalisation in just eight months, the new CEO, Christian Wojczewski, is taking action and closing non-profitable areas.
Investigating substrate selectivity of nitrogenase enzymes in phototrophic R. capsulatus bacteria, German microbiologist have found one converting CO2 to formiate and methane opening the way to fossil oil-free hydrocarbon synthesis
German diagnostics specialist SphingoTec GmbH has closed a €5m Series C financing round led by Think.Health Ventures.
A Dutch-German resarch team together with Evotec SE have presented a new class of vancomycin derivatives with good safety profile that kill multi-resistant, Gram-positive bugs.
After Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
French bioplastics recycling specialist Carbios SAS and British recycling and waste management company FCC Environment want to establish a PET biorecycling facility in the UK.
The US Food & Drug Administration has granted accelerated approval to Adaptimmune’s Tecelra as the world’s first therapy with genetically engineered T cells to fight a solid tumour.
French-Austrian vaccine maker Valneva SE has secured exclusive worldwide rights to commercialise LimmaTech Biologics AG’s S4V Shigella vaccine that will be tested in two Phase II trials starting in H2/2024.
With an investment of its venture arm (BI-VF), Boehringer Ingelheim underlines its committment to expand the reach of cancer immune therapies. The Series A financing in Chinese Synthetica Pioneering that engineers oncolytic bacteria to deliver toxic payloads or modulators of the tumour environment to solid tumours follows an investment in T3 Pharmaceuticals.
As one of the last Big Pharma companies, GlaxoSmithKline plc has inked a drug discovery licence option deal for up to 10 programmes with US-based biotech platform company supplier Flagship Pioneering Inc.